Spontaneous release of neuropeptide Y tonically inhibits recurrent mossy fiber synaptic transmission in epileptic brain.
In the pilocarpine model of temporal lobe epilepsy, mossy fibers coexpress the inhibitory transmitter neuropeptide Y (NPY) with glutamate. The effects of endogenous and applied NPY on recurrent mossy fiber synaptic transmission were investigated with the use of whole-cell voltage-clamp and field recordings in rat hippocampal slices. Applied NPY reversibly inhibited synaptic transmission at recurrent mossy fiber synapses on dentate granule cells but not at perforant path or associational-commissural synapses. It also reduced the frequency of miniature EPSCs (mEPSCs) in granule cells from epileptic, but not control, rats and depressed granule cell epileptiform activity dependent on the recurrent mossy fiber pathway. These actions of NPY were mediated by activation of presynaptic Y2 receptors. The Y2 receptor antagonist (S)-N2-[[1-[2-[4-[(R,S)-5,11-dihydro-6(6H)-oxodibenz[b,e]azepin-11-yl]-1-piperazinyl]-2-oxoethyl]cyclopentyl]acetyl]-N-[2-[1,2-dihydro-3,5(4H)-dioxo-1,2-diphenyl-3H-1,2,4-triazol-4-yl]ethyl]argininamide (BIIE0246) not only blocked the effects of NPY but also enhanced recurrent mossy fiber synaptic transmission, the frequency of mEPSCs, and the magnitude of mossy fiber-evoked granule cell epileptiform activity when applied by itself. Several observations supported the selectivity of BIIE0246. These results suggest that even the spontaneous release of NPY (or an active metabolite) from recurrent mossy fibers is sufficient to depress glutamate release from this pathway. Tonic release of NPY accounts at least partially for the low probability of glutamate release from recurrent mossy fiber terminals, impedes the ability of these fibers to synchronize granule cell discharge, and may protect the hippocampus from seizures that involve the entorhinal cortex. This pathway may synchronize granule cell discharge more effectively in human brain than in rat because of its lower expression of NPY.
Tu
Bin
B
Department of Pharmacology and Cancer Biolog, Duke University Medical Center, Durham, North Carolina 27710, USA.
Timofeeva
Olga
O
Jiao
Yiqun
Y
Nadler
J Victor
JV
D015763:2-Amino-5-phosphonovalerate / Q000494:pharmacology; D000818:Animals; D001120:Arginine / Q000031:analogs & derivatives / Q000494:pharmacology; D001552:Benzazepines / Q000494:pharmacology; D001640:Bicuculline / Q000494:pharmacology; D003292:Convulsants / Q000633:toxicity; D018891:Dentate Gyrus / Q000737:chemistry / Q000648:ultrastructure; D019706:Excitatory Postsynaptic Potentials / Q000187:drug effects; D006624:Hippocampus / Q000737:chemistry / Q000503:physiopathology* / Q000648:ultrastructure; D008297:Male; D019599:Mossy Fibers, Hippocampal / Q000378:metabolism* / Q000503:physiopathology; D009478:Neuropeptide Y / Q000378:metabolism*; D018408:Patch-Clamp Techniques; D019580:Perforant Pathway / Q000187:drug effects; D010862:Pilocarpine / Q000633:toxicity; D051381:Rats; D017207:Rats, Sprague-Dawley; D016194:Receptors, N-Methyl-D-Aspartate / Q000187:drug effects / Q000502:physiology; D017476:Receptors, Neuropeptide Y / Q000037:antagonists & inhibitors / Q000502:physiology; D013226:Status Epilepticus / Q000139:chemically induced / Q000473:pathology / Q000503:physiopathology*; D009435:Synaptic Transmission / Q000502:physiology*; D013779:Tetrodotoxin / Q000494:pharmacology
D001552:Benzazepines; D003292:Convulsants; D009478:Neuropeptide Y; D016194:Receptors, N-Methyl-D-Aspartate; D017476:Receptors, Neuropeptide Y; C095889:neuropeptide Y2 receptor; D010862:Pilocarpine; D013779:Tetrodotoxin; D015763:2-Amino-5-phosphonovalerate; D001120:Arginine; C403256:BIIE 0246; D001640:Bicuculline
Trends Neurosci. 1999 Jan;22(1):25-30
10088996
J Neurophysiol. 1999 Apr;81(4):1645-60
10200201
Neuroscience. 1999;90(4):1445-61
10338311
J Neurophysiol. 1999 Jul;82(1):478-83
10400974
Epilepsy Res. 1999 Aug;36(1):31-42
10463848
Exp Neurol. 1999 Sep;159(1):73-83
10486176
J Neurophysiol. 1999 Oct;82(4):1883-94
10515977
Eur J Pharmacol. 1999 Nov 19;384(2-3):R3-5
10611450
Brain Res. 1999 Nov 27;848(1-2):153-66
10612707
Br J Pharmacol. 2000 Mar;129(6):1075-88
10725255
J Neurosci. 2000 Aug 15;20(16):6144-58
10934264
Eur J Pharmacol. 2000 Sep 15;404(1-2):133-6
10980271
J Neurophysiol. 2000 Nov;84(5):2380-9
11067980
J Physiol. 2001 Feb 15;531(Pt 1):81-94
11179393
Eur J Neurosci. 2001 Feb;13(4):657-69
11207801
J Neurosci. 2001 Aug 1;21(15):5804-12
11466452
Brain Res. 2001 Oct 5;915(1):58-69
11578620
J Neurophysiol. 2002 Jan;87(1):558-66
11784771
Br J Pharmacol. 2002 Jun;136(4):502-9
12055128
J Neurosci. 2002 Jul 15;22(14):6052-61
12122066
J Comp Neurol. 2003 Apr 21;459(1):44-76
12629666
J Neurosci. 2003 Jun 15;23(12):5381-90
12832564
Epilepsy Res Suppl. 1992;7:301-13
1334669
J Neurophysiol. 2003 Oct;90(4):2536-47
14534276
J Neurosci. 2003 Oct 22;23(29):9639-49
14573544
Neurochem Res. 2003 Nov;28(11):1649-58
14584819
Epilepsy Res Suppl. 1992;7:223-34
1466768
Brain Res. 1992 Feb 28;573(2):305-10
1504768
Epilepsy Curr. 2003 Mar;3(2):53-58
15309085
Neuropeptides. 2004 Aug;38(4):245-52
15337376
J Neurosci. 2004 Oct 6;24(40):8741-51
15470140
Brain Res. 1992 May 1;579(1):119-27
1623399
Br J Pharmacol. 1991 Jan;102(1):41-4
1646061
Neuroscience. 1991;42(2):351-63
1716744
Ann Neurol. 1989 Sep;26(3):321-30
2508534
Neurosci Lett. 1989 May 8;99(3):351-5
2542848
Brain Res. 1989 Aug 28;495(2):387-95
2569920
J Neurosci Methods. 1989 Dec;30(3):203-10
2607782
J Neurophysiol. 1989 Jul;62(1):126-35
2754466
J Physiol. 1987 Feb;383:285-99
2821236
J Neurosci. 1988 Oct;8(10):3827-37
2848110
J Physiol. 1986 Nov;380:175-89
2886653
J Neurosci. 1985 Apr;5(4):1016-22
3981241
Electroencephalogr Clin Neurophysiol. 1972 Mar;32(3):281-94
4110397
Brain Res. 1983 Nov 28;280(1):25-40
6652478
Histochemistry. 1981;71(1):1-16
6785259
Epilepsia. 1995 Jun;36(6):543-58
7555966
Epilepsia. 1993 Nov-Dec;34(6):985-95
7694849
J Comp Neurol. 1995 Feb 20;352(4):515-34
7721998
J Neurosci. 1995 May;15(5 Pt 2):3990-4004
7751960
Br J Pharmacol. 1994 Nov;113(3):737-40
7858862
Hippocampus. 1993 Jan;3(1):103-11
8395947
Neuroscience. 1995 Dec;69(3):831-45
8596652
J Neurosci. 1996 Jul 15;16(14):4438-48
8699254
J Neurosci. 1996 Sep 15;16(18):5883-95
8795640
Regul Pept. 1996 Aug 27;65(1):71-7
8876038
Hippocampus. 1996;6(4):347-470
8915675
Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):13304-9
8917586
J Neurophysiol. 1996 Nov;76(5):3159-68
8930263
Regul Pept. 1996 Nov 14;67(1):33-7
8952003
J Pharmacol Exp Ther. 1997 Apr;281(1):291-6
9103509
J Neurophysiol. 1997 May;77(5):2685-96
9163384
J Neurosci. 1997 Oct 1;17(19):7503-22
9295396
Epilepsy Res Suppl. 1996;12:137-44
9302512
Exp Brain Res. 1997 Aug;116(1):186-90
9305828
J Neurophysiol. 1997 Sep;78(3):1651-61
9310450
J Neurosci. 1997 Nov 1;17(21):8169-77
9334392
J Neurophysiol. 1998 Jan;79(1):418-29
9425210
Mol Pharmacol. 1998 Jan;53(1):6-13
9443927
J Neurochem. 1998 Apr;70(4):1615-22
9523578
J Neurochem. 1998 May;70(5):1950-63
9572279
Brain Res Brain Res Rev. 1998 May;26(2-3):154-66
9651513